SavedAdd your journal

Journals / Turkish Journal of Obstetrics and Gynecology / 2017 / Cilt: 14 - Sayı: 4

Düşük over yanıtlı hasta grubunda corifollitropin alfa ve rekombinant folikül uyarıcı hormonun in vitro fertilizasyon sikluslarında karşılaştırılması

Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles

Süleyman AKARSU
Sibel DEMİR
FUNDA GÖDE
Ahmet Zeki IŞIK
Pages
199–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The implantation rate was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 2, whereas the clinical pregnancy rates were 16.3% and 17.2%, respectively.Conclusion: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA or rFSH use in the antagonist cycles in poor-responder patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to compare the effect of corifollitropin alfa (CFA) and recombinant follicle-stimulating hormone (rFSH) in poorresponder patients undergoing antagonist cycles.Materials and Methods: The study was a retrospective analysis of the treatment results of 214 poor responder patients who had been admitted to the In Vitro Fertilization Unit of İzmir Medical Park Hospital between November 2014 and November 2016.
📊
Key Findings & Data:Intracytoplasmic sperm injections were performed in 38 patients (group 1) with CFA, and the remaining 176 (group 2) with rFSH for controlled ovarian hyperstimulation.Results: The age, body mass index, anti-müllerian hormone level, duration of infertility, duration of induction and antral follicle number were similar in the two groups.
💡
Conclusion & Impact:The implantation rate was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 2, whereas the clinical pregnancy rates were 16.3% and 17.2%, respectively.Conclusion: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA or rFSH use in the antagonist cycles in poor-responder patients
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to compare the effect of corifollitropin alfa (CFA) and recombinant follicle-stimulating hormone (rFSH) in poorresponder patients undergoing antagonist cycles.Materials and Methods: The study was a retrospective analysis of the treatment results of 214 poor responder patients who had been admitted to the In Vitro Fertilization Unit of İzmir Medical Park Hospital between November 2014 and November 2016. Intracytoplasmic sperm injections were performed in 38 patients (group 1) with CFA, and the remaining 176 (group 2) with rFSH for controlled ovarian hyperstimulation.Results: The age, body mass index, anti-müllerian hormone level, duration of infertility, duration of induction and antral follicle number were similar in the two groups. There was no difference in the total aspirated oocyte counts, mature oocyte ratio, fertilization rate, implantation rate, and clinical pregnancy rates between the two groups. The implantation rate was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 2, whereas the clinical pregnancy rates were 16.3% and 17.2%, respectively.Conclusion: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA or rFSH use in the antagonist cycles in poor-responder patients

Özet

Amaç: Bu çalışmanın amacı düşük over yanıtlı hasta grubunda antagonist sikluslarda korifollitropin alfa (CFA) ve rekombinant folikül stimülant hormonun (rFSH) etkinliğini karşılaştırmaktı.Gereç ve Yöntemler: Çalışma İzmir Medical Park Hastanesi İn Vitro Fertilizasyonu Merkezi'nde Kasım 2014 ile Kasım 2016 tarihleri arasında düşük over yanıtlı toplam 214 hastanın kayıtlarından retrospektif olarak yapıldı. Otuz sekiz hastaya CFA (grup 1), 176 hastaya (grup 2) rFSH kulanılarak kontrollü ovaryan stimülasyon yapıldı.Bulgular: Yaş, vücut kitle indeksi, anti-müllerian hormon düzeyi, infertilite süresi, indüksiyon süresi ve antral follikül sayısı her iki grupta aynıydı. Aspire edilen toplam oosit sayısı, matür oosit oranı, fertilizasyon oranı, implantasyon oranı ve klinik gebelik oranı açısından her iki grup arasında fark gözlenmedi. İmplantasyon oranı grup 1'de 9/38 (%23,6) ve grup 2'de 42/176 (%23,8) iken; klinik gebelik oranı sırasıyle grup 1'de %16,3 ve grup 2'de %17,2 idi.Sonuç: Düşük over yanıtlı hasta gruplarında yapılan antagonist sikluslarda CFA ve rFSH kullanımının oosit sayısı, fertilizasyon oranı, implantasyon oranı ve klinik gebelik oranı arasında fark yoktur

🔖

Cite This Article

AKARSU, S., DEMİR, S., GÖDE, F., IŞIK, A. Z. (2017). Düşük over yanıtlı hasta grubunda corifollitropin alfa ve rekombinant folikül uyarıcı hormonun in vitro fertilizasyon sikluslarında karşılaştırılması. Turkish Journal of Obstetrics and Gynecology, Cilt: 14 - Sayı: 4, 199–202. https://ajindex.com/articles/376314

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009;15:309-21
  2. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A 1992;89:4304-8
  3. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online 2010;21:593-601
  4. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004;89:2062-70
  5. Bouloux PM, Handelsman DJ, Jockenhövel F, Nieschlag E, Rabinovici J, Frasa WL, et al. First human exposure to FSHCTP in hypogonadotrophic hypogonadal males. Hum Reprod 2001;16:1592-7
  6. Polyzos NP, Devroey P. A systematic review of randomized trials fort he treatment of poor ovarian responders:is there any light at the end of the tunnel? Fertil Steril 2011;96:1058-61
  7. Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, et al. ESHRE Capri Workshop Group: Fertility and ageing. Hum Reprod Update 2005;11:261-76
  8. Younis JS. Ovarian aging: latest thoughts on assesment and management. Curr Opin Obstet Gynecol 2011;23:427-34
  9. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definitionof ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616-24
  10. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, noninferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063-72
  11. Abyholm T, Andersen AN, Balen AH, Braat DD, Devroey P, D’Hooghe TH, et al. Corifollitropin Alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sus